OncLive TV

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses global vaccination and screening for cervical cancer.

Alex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses the use of biosimilars in the treatment of patients with cancer.

Deborah Krakow, MD, professor and chair, Department of Obstetrics and Gynecology, professor of Orthopaedic Surgery and Human Genetics, University of California, Los Angeles, discusses genetic testing in patients with ovarian cancer.

Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses combination clinical trials of PARP inhibitors in patients with ovarian cancer.

Lindsay Frazier, MD, institute physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, associate professor of pediatrics, Harvard Medical School, discusses the Malignant Germ Cell International Consortium (MaGIC) in pediatric and rare tumors.

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer.

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the impact of the FDA-approval of the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst).

Sanaz Memarzadeh, MD, PhD, gynecologic oncologist, professor of obstetrics and gynecology, University of California, Los Angeles, discusses p53 reactivation in the treatment of patients with ovarian cancer.

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.

Charlotte Kubicky, MD, PhD, associate professor of radiation medicine, School of Medicine, medical director, Tuality Oregon Health and Science Cancer Center, Oregon Health and Science University, discusses the optimal use of radiation in the treatment of patients with breast cancer.

Kathleen Essel, MD, fellow, University of Oklahoma Health Science Center, discusses adverse events with bevacizumab (Avastin) in ovarian cancer.

Farah Succaria, MD, postdoctoral fellow, Johns Hopkins Medicine, discusses the potential for combination immunotherapy in the treatment of patients with head and neck cancer.

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses emerging agents in myelofibrosis.

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of immunotherapy in the treatment of patients with multiple myeloma.

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.

Joshua G. Cohen, MD, assistant professor, Division of Gynecologic Oncology, University of California, Los Angeles, discusses the evolution of surgery in the treatment of patients with ovarian cancer.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses misconceptions about biosimilars in oncology.

James Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the evolution of radiation therapy in the treatment of patients with oligometastatic non–small cell lung cancer.

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses targeted therapies in gastric/esophageal cancers.

James L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses immunotherapy efforts in prostate cancer.

Bradley J. Monk, MD, FACOG, FACS, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Arizona Oncology, discusses the FORWARD I trial in ovarian cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses primary and adaptive resistance to immunotherapy in non–small cell lung cancer (NSCLC).

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses acquired resistance to CDK 4/6 inhibitors in breast cancer.

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the Precision Promise trial for patients with metastastic pancreatic cancer.

Paul Mayor, MD, Gynecologic Oncology Fellow, Roswell Park Cancer Institute, discusses neuroendocrine carcinoma in gynecologic tumors.

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses remaining challenges with chimeric antigen receptor (CAR) T-cell therapy.

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses new combinations with immunotherapy in renal cell carcinoma.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.